ARCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcturus Therapeutics Holdings Inc (ARCT) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the stock is trading near its cash position and analysts see potential upside, the company's weak financial performance, lack of recent positive news, and absence of strong trading signals suggest a cautious approach. Holding the stock or waiting for further developments may be more prudent.
The MACD is slightly positive at 0.125, indicating mild bullish momentum, but it is contracting. RSI is at 78.486, in the neutral zone, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price direction. The stock is trading near its resistance level (R1: 8.944), which could act as a barrier to further upside.
The company's RNA platform and two mid-stage programs for rare diseases are considered promising. The stock is trading near its cash position, which some analysts view as a sign of mispricing.
The company's financial performance in Q4 2025 was weak, with revenue down 68.39% YoY and net income at -$29.08M. EPS also dropped by 7.21% YoY. No recent news or congress trading data is available to provide additional positive sentiment. Analyst price target reductions and cautious tones from some firms highlight execution risks.
In Q4 2025, revenue dropped significantly by 68.39% YoY to $7.2M. Net income was -$29.08M, a slight decline of 3.09% YoY. EPS fell to -1.03, down 7.21% YoY. Gross margin remained stable at 100%. Overall, the financials indicate declining growth and profitability.
Analysts maintain a generally positive outlook, with multiple Buy ratings and price targets significantly above the current price. However, recent price target reductions reflect concerns about execution and the removal of certain revenue streams from models. Analysts believe 2026 could be pivotal for the stock, driven by progress in its rare disease programs.
